Commerzbank Ag set a €76.00 ($90.48) target price on MorphoSys AG (ETR:MOR) in a research report released on Thursday. The firm currently has a buy rating on the stock.

A number of other equities analysts have also recently issued reports on the company. Berenberg Bank set a €68.00 ($80.95) target price on MorphoSys AG and gave the stock a buy rating in a report on Wednesday, August 16th. Independent Research GmbH set a €77.00 ($91.67) price target on MorphoSys AG and gave the company a buy rating in a report on Monday, August 7th. Deutsche Bank AG set a €90.00 ($107.14) price target on MorphoSys AG and gave the company a buy rating in a report on Monday, August 7th. J P Morgan Chase & Co set a €62.00 ($73.81) price target on MorphoSys AG and gave the company a neutral rating in a report on Friday, August 4th. Finally, Goldman Sachs Group, Inc. (The) set a €55.00 ($65.48) price target on MorphoSys AG and gave the company a neutral rating in a report on Friday, August 4th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. MorphoSys AG currently has an average rating of Buy and an average target price of €69.57 ($82.82).

MorphoSys AG (ETR MOR) opened at 60.914 on Thursday. The company’s 50-day moving average price is €60.50 and its 200-day moving average price is €58.54. The company’s market capitalization is €1.77 billion. MorphoSys AG has a 52 week low of €35.72 and a 52 week high of €70.90.

COPYRIGHT VIOLATION WARNING: “Commerzbank Ag Analysts Give MorphoSys AG (MOR) a €76.00 Price Target” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/09/03/commerzbank-ag-analysts-give-morphosys-ag-mor-a-76-00-price-target.html.

About MorphoSys AG

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Analyst Recommendations for MorphoSys AG (ETR:MOR)

Receive News & Stock Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related stocks with our FREE daily email newsletter.